Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

17.5%

11 terminated/withdrawn out of 63 trials

Success Rate

82.0%

-4.5% vs industry average

Late-Stage Pipeline

59%

37 trials in Phase 3/4

Results Transparency

86%

43 of 50 completed trials have results

Key Signals

1 recruiting43 with results6 withdrawn

Enrollment Performance

Analytics

Phase 3
27(45.0%)
Phase 2
17(28.3%)
Phase 4
10(16.7%)
Phase 1
4(6.7%)
N/A
2(3.3%)
60Total
Phase 3(27)
Phase 2(17)
Phase 4(10)
Phase 1(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (63)

Showing 20 of 63 trials
NCT00244816Phase 2Completed

Taxoprexin® Treatment for Advanced Eye Melanoma

Role: lead

NCT00422877Phase 2Terminated

Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

Role: lead

NCT00249262Phase 2Completed

Taxoprexin Treatment for Advanced Skin Melanoma

Role: lead

NCT01471639Not ApplicableCompleted

An Efficacy and Safety Trial of Intranasal Ketorolac in Emergency Department Patients for the Treatment of Acute Pain

Role: collaborator

NCT00243867Phase 3Completed

Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer

Role: lead

NCT00087776Phase 3Terminated

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

Role: lead

NCT07053475Phase 4Recruiting

IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches

Role: collaborator

NCT01290302Phase 1Completed

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

Role: lead

NCT02478281Phase 1Completed

Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults

Role: lead

NCT01950247Phase 4Completed

Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron

Role: lead

NCT00239616Phase 2Completed

Pharmacokinetic of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin

Role: lead

NCT00236964Phase 3Completed

Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis

Role: lead

NCT02527213Phase 3Withdrawn

Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy

Role: lead

NCT00685815Phase 2Completed

Intravenous Iron Metabolism in Restless Legs Syndrome

Role: lead

NCT05816265Phase 4Enrolling By Invitation

Effects of IV Iron Replacement on Exercise Capacity in Individuals With Heart Failure

Role: collaborator

NCT00740246Phase 3Completed

Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia

Role: lead

NCT02826681Phase 2Terminated

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

Role: lead

NCT05661682Phase 4Withdrawn

Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese Safety

Role: lead

NCT06690450Phase 4Completed

Safety and Tolerability of 200mg and 100mg of Venofer Administered to Hemodialysis(HD) Patients

Role: lead

NCT05677126Phase 4Withdrawn

Tralement vs. Fixed-dose Trace Element Combination Product in Patients >3 to 17 Years of Age Requiring Long-term PN

Role: lead